Cure Research/June 26, 2026/2 min read

Lab-Made Insulin Cells Show Promise in Small Group of Type 1 Diabetes Patients

Vertex Pharmaceuticals reported that 10 of 12 study participants became insulin-independent for at least one year using transplanted cells made in the laboratory. All participants required ongoing immunosuppression medication to prevent rejection.

Community video — lay discussion, not peer-reviewed research

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cureresearchclinical trial

Key takeaways

In a subset of 12 patients from Vertex's larger VX880 trial, 10 achieved insulin independence for one year or longer
The insulin-producing cells were created in a laboratory, which could eventually help address cell availability challenges
All participants must take immunosuppression drugs to prevent the body from rejecting the transplanted cells, which carries its own health risks
This research involved patients with severe Type 1 diabetes and severe low blood sugar episodes
This is early-stage research; results in 12 people do not yet represent a broadly applicable treatment

What Happened in This Study

Vertex Pharmaceuticals shared results from their VX880 clinical trial involving 50 participants total. Among 12 of these patients, researchers reported that 10 became insulin-independent—meaning they no longer needed insulin injections—and maintained that status for at least one year. The remaining two participants did not achieve full insulin independence but did produce some of their own insulin and showed improved blood sugar control, with A1C levels dropping below 7% and time-in-range reaching 70% or higher.

The Cells Are Lab-Made, Not Donor-Derived

A significant element of this research is that the insulin-producing cells were created in a laboratory rather than harvested from organ donors. This approach could address one of the major barriers to cell transplant therapies: the limited availability of donor organs. If this method proves safe and effective over longer periods, manufacturing cells in the lab could eventually make the treatment more scalable.

Immunosuppression Remains Essential—and Challenging

All participants in this group required ongoing immunosuppression medications to prevent their bodies from rejecting the transplanted cells. These drugs suppress immune function, which means patients are at higher risk for infections and other complications. For the participants in this trial—who had severe Type 1 diabetes and experienced frequent dangerous low blood sugar episodes—the research team determined that the benefits outweighed these risks. However, immunosuppression is a serious consideration that must be weighed carefully in any future treatment decisions.

This Is Early Research—More Data Ahead

These results come from a small group within a larger ongoing trial. Vertex is expected to release findings from additional participants in the coming months. This early data is encouraging but represents just one step in a longer research process. Many questions remain about long-term safety, how long the benefits last, and whether results in this carefully selected group will apply more broadly to other people with Type 1 diabetes.

Evidence label

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.